Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions
DENVER, March 27, 2025--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial Intelligence-based Quantitative Computed Tomography's (AI-QCT's) role in identifying risks of future major adverse cardiovascular events (MACE) in women. Onsite, Cleerly will demonstrate the company's AI-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD).
Late-Breaking Clinical Trial Presentation
In the session "Clinical and Investigative Horizons" on March 31st at 9:00 AM, Dr. Gudrun Feuchtner will present late-breaking clinical research titled "Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2," on behalf of the CONFIRM2 investigators. This groundbreaking research will shine a light on the potential role of Cleerly's AI-QCT for measuring disease in women, in whom coronary artery disease is often underdiagnosed and undertreated. CONFIRM2 is one of the few studies in which about 50% of the participants are female. With a diverse trial population of 3,500 participants from sites across 11 countries, this study highlights the generalized applicability of the results in addressing cardiovascular health disparities.
Sessions and Abstracts
Cleerly's founder and CEO, Dr. James Min, will be featured on the Health Equity Panel on March 30th from 2:30 - 3:30 PM. This session, titled "Championing Communities of Health: A Cross-Industry Panel Discussion on Community Education, Cardiovascular Disease Prevention, and Screening Programs," will address critical issues surrounding health equity and the importance of community engagement in cardiovascular health.
Cleerly will also participate in a Lounge & Learn Session titled "Increasing Female Physician Leadership in Clinical Trials" on March 30th from 1:00 - 1:30 PM in the Education Zone, Theater 1 of the Lounge and Learn Pavilion. Additionally, Cleerly will present six additional abstracts throughout the conference, showcasing advancements in heart health technology and research.
Visit Cleerly at Booth #16033
Stop by and learn more about Cleerly at booth #16033, where a coffee bar with barista service will be available for all visitors. The Cleerly team will be available to demonstrate the technology, including its COMPARE feature, which enables clinicians to track the progression of plaque over time.
Attendees can also stop by Cleerly's "Meet Cleerly Leadership" event on Sunday, March 30th from 12:30 to 1:30 PM, for an opportunity to talk with Cleerly leadership and enjoy a complimentary lunch-style buffet. To see a full schedule of Cleerly presentations or schedule a meeting with Cleerly leadership, please visit this link.
About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327234965/en/
Contacts
Cleerly Media Contact Christy Sievertpress@cleerlyhealth.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
41 minutes ago
- TechCrunch
Google says its updated Gemini 2.5 Pro AI model is better at coding
In Brief Google on Thursday announced an update to its Gemini 2.5 Pro preview model that the company claims is better at certain programming tasks. The company's calling it an 'updated preview,' building on the upgrade to Gemini 2.5 Pro that Google announced around a month ago. Google says the model will roll out in general availability in a 'couple of weeks,' and is available starting today in its AI developer platforms AI Studio and Vertex AI and the Gemini app. Image Credits:Google '[Gemini 2.5 Pro] continues to excel at coding, leading on difficult coding benchmarks,' Google writes in a blog post. 'It also shows top-tier performance [on] highly challenging benchmarks that evaluate a model's math, science, knowledge, and reasoning capabilities.' So what else is new? Google says it addressed feedback from its previous 2.5 Pro release, improving the model's style and structure. Now, 2.5 Pro can be 'more creative with better-formatted responses,' Google claims.
Yahoo
an hour ago
- Yahoo
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J., June 05, 2025--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. "FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too," said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. "For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance." "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients," said Nicole Jacque, co-founder of FIP Global Cats. "Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP." Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About WedgewoodWedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit View source version on Contacts Jennifer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J.--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment." Share GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. 'FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,' said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. 'For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.' "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,' said Nicole Jacque, co-founder of FIP Global Cats. 'Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.' Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About Wedgewood Wedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit
